Impact News +++ Why New Fortress Energy Stock Is Soaring Today (Fool) +++ NEW FORTRESS ENERGY Aktie +5,45%

MARKER THERAPEUTICS Aktie

>Performance

1 Woche: -6,9%

1 Monat: +83,5%

3 Monate: +83,5%

6 Monate: -6,9%

1 Jahr: -72,0%

laufendes Jahr: -60,6%

>MARKER THERAPEUTICS Aktie

Name:

MARKER THERAPEUTICS INC.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US57055L2060 / A3D5YK

Symbol/ Ticker:

GX1 (Frankfurt) / MRKR (NASDAQ)

Kürzel:

FRA:GX1, ETR:GX1, GX1:GR, NASDAQ:MRKR

Index:

Webseite:

https://markertherapeutic..

Profil:

Marker Therapeutics, Inc., a clinical-stage immuno..
>Volltext..

Marktkapitalisierung:

18.05 Mio. EUR

Unternehmenswert:

1.9 Mio. EUR

Umsatz:

4 Mio. EUR

EBITDA:

-12.29 Mio. EUR

Nettogewinn:

-12.19 Mio. EUR

Gewinn je Aktie:

-1.05 EUR

Schulden:

Liquide Mittel:

16.15 Mio. EUR

Operativer Cashflow:

-12.63 Mio. EUR

Bargeldquote:

5.66

Umsatzwachstum:

-12.99%

Gewinnwachstum:

-48.42%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MARKER THERAPEUTICS, MARKER THERAPEUTIC

Letzte Datenerhebung:

17.12.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 16.67 Mio. St.

Frei handelbar: 81.17%

Leerverk. Aktien: 1.4%

Rückkaufquote: -116.93%

Mitarbeiter: 5

Umsatz/Mitarb.: 1.12 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 477.43%

Bewertung:

KGV: -

KGV lG: -

KUV: 4.96

KBV: 1.15

PEG-Ratio: -0.08

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -304.54%

Operative Marge: -307.02%

Managementeffizenz:

Gesamtkaprendite: -87.6%

Eigenkaprendite: -110.67%

>Peer Group

Es sind 599 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

14.11.25 - 13:33	Marker Therapeutics GAAP EPS of -$0.12 beats by $0.33, revenue of $1.23M beats by $0.51M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.25 - 13:03	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire EN)
	APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma ...

05.11.25 - 13:33

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors (GlobeNewswire EN)

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025....

03.11.25 - 15:18	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting (GlobeNewswire EN)
	Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data...

06.10.25 - 13:33	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program (GlobeNewswire EN)
	Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment...

28.08.25 - 14:03

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025 in New York....

26.08.25 - 13:03	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma (GlobeNewswire EN)
	Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR)...

30.07.25 - 14:03

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire EN)

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference taking place from August 12-14, 2025 in Boston, Massachusetts....

17.06.25 - 14:03

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma (GlobeNewswire EN)

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker's lead Multi-Antigen Recognizing (MAR)-T cell therapy....

20.05.25 - 14:03	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma (GlobeNewswire EN)
	Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity...

19.05.25 - 14:03	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies (GlobeNewswire EN)
	Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025...

01.04.25 - 14:03

Marker Therapeutics to Present at Canaccord Genuity′s Horizons in Oncology Conference (GlobeNewswire EN)

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference....

31.03.25 - 14:54	Marker Therapeutics GAAP EPS of -$1.19, revenue of $6.59M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 14:48	Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results (GlobeNewswire EN)
	Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses...

25.02.25 - 13:06

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire EN)

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025....

27.12.24 - 01:01	Insiderhandel: Aufsichtsrat kauft Aktien von Marker Therapeutics im Wert von 35472 USD (Insiderkauf)
	Elms, Steve - Aufsichtsrat - Tag der Transaktion: 2024-12-23...

24.12.24 - 04:01	Insiderhandel: Insider kauft Aktien von Marker Therapeutics im Wert von 1773600 USD (Insiderkauf)
	New Enterprise Associates 16, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2024-12-23...

19.12.24 - 17:45	Marker Therapeutics sells 5.03M shares at $3.20 in private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.12.24 - 14:09	Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma (GlobeNewswire EN)
	APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)...

19.12.24 - 14:09	Marker Therapeutics Announces $16.1 Million Private Placement (GlobeNewswire EN)
	Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram